Prenetics Global Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Prenetics Global Limited (PRE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Prenetics Global Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 92M vs 12,882M combined for tracked competitors (0.7% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs holding steady (+1.9%) for its tracked peer group.
- Growth: Prenetics Global Limited generated 201.9% revenue growth year over year in Q4 2025, vs 13.7% for its tracked competitors combined.
- Profitability: Its -43.6% net margin compares with 9.6% for the peer group.
- Scale: Prenetics Global Limited ranks #15 of 32 companies by market capitalization in the Laboratory Analytical Instruments industry, holding 0.1% of industry market cap.
- Peer revenue share: Prenetics Global Limited accounted for 2.7% of combined revenue among its tracked peer group, up from 1.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.26M compares with $0.50M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PRE Sales vs. its Competitors, Q4 2025
Prenetics Global Limited reported revenue growth of 201.94 % year on year in Q4 2025, above its competitors' combined revenue growth of 13.67 %.
With a net margin of -43.55 %, Prenetics Global Limited reported lower profitability than its competitors (9.62 %).
Prenetics Global Limited generated 2.72 % of the combined sales of its peer group, up from 1.04 % a year earlier.
Prenetics Global Limited vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Prenetics Global Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Prenetics Global Limited | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Prenetics Global Limited's competitor groups requires a Commercial License.
For context: the Laboratory Analytical Instruments industry grew revenue 13.3% year over year, combined, vs 201.9% for Prenetics Global Limited. Prenetics Global Limited's share of combined industry revenue moved from 0.32% to 0.85%, a gain of 0.53 percentage points.
Prenetics Global Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Prenetics Global Limited | No | Yes | Yes | No |
| Competitors combined (8) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PRE Stock Performance relative to its Competitors
PRE Stock Performance relative to High-Confidence Competitors
PRE Stock Performance relative to Similar-Size Competitors
PRE Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Caredx Inc | 282.9% | Outperformed |
| 2 | Illumina Inc | 282.9% | Outperformed |
| 3 | Guardant Health Inc | 282.9% | Outperformed |
| 4 | Natera Inc | 282.9% | Outperformed |
| 5 | Revvity Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Prenetics Global Limited's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Prenetics Global Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Prenetics Global Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Prenetics Global Limited | - | 91.79 |
| Natera Inc | 58,525.17 | 2,707.08 |
| Illumina Inc | 40,655.16 | 4,493.00 |
| Guardant Health Inc | 23,218.51 | 1,183.11 |
| Revvity Inc | 16,639.42 | 2,911.81 |
| Caredx Inc | 3,538.17 | 458.09 |
| SUBTOTAL | 143,574.49 | 13,147.77 |
Sign in to see all competitors of Prenetics Global Limited.
Sources: Prenetics Global Limited's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Prenetics Global Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Prenetics Global Limited's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nestlé Health Science S.A. | Named by the company | 85% |
| 23andMe, Inc. | Named by the company | 85% |
| Elysium Health | Named by the company | 85% |
| myDNA Life Ltd. | Named by the company | 85% |
| Thorne, Inc. | Named by the company | 85% |
| Athletic Greens, Inc. (AG1) | Named by the company | 85% |
| Huel Limited | Named by the company | 85% |
| Ritual, Inc. | Named by the company | 85% |
| Amazon.com | Named by the company | 85% |
| Futura Genetics | Named by the company | 85% |
| MyHeritage Ltd. | Named by the company | 85% |
| Bodybuilding.com | Named by the company | 85% |
| Invitae Corporation | Named by the company | 85% |
| The Vitamin Shoppe | Named by the company | 85% |
| Ancestry.com LLC | Named by the company | 85% |
| GNC Holdings, LLC | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Prenetics Global Limited's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Prenetics Global Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Natera Inc | Reportable 100.00 % |
| Illumina Inc | Sequencing 90.94 % |
| Guardant Health Inc | Reportable 100.00 % |
| Caredx Inc | Reportable 100.00 % |
| Fulgent Genetics Inc | Precision Diagnostics 57.08 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Prenetics Global Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Prenetics Global Limited | - | 262,257 | -114,223 |
| Natera Inc | 58,525 | 440,892 | -31,327 |
| Illumina Inc | 40,655 | 3,510,156 | 644,531 |
| Guardant Health Inc | 23,219 | 472,109 | -180,940 |
| Revvity Inc | 16,639 | 264,710 | 21,596 |
| Caredx Inc | 3,538 | 598,809 | 145,114 |
| PEERS TOTAL | 143,574 | 496,104 | 3,587 |
Sign in to see all peers for Prenetics Global Limited.
Prenetics Global Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Natera Inc | United States 98.24 % |
| Illumina Inc | United States and Canada 56.34 % |
| Guardant Health Inc | United States 94.35 % |
| Caredx Inc | United States 96.56 % |
| Fulgent Genetics Inc | Other countries 4.93 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Prenetics Global Limited.
Prenetics Global Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 28 companies in Prenetics Global Limited's industry classification, broader than the peer set above. Market cap in millions of $.Prenetics Global Limited ranks #15 of 28 companies by market capitalization in its industry, holding 0.11 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,464, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Agilent Technologies inc | 48,469 | 21.30 % |
| 2 | Waters Corporation | 42,742 | 18.78 % |
| 3 | Illumina Inc | 41,591 | 18.27 % |
| 4 | Mettler toledo International Inc | 30,558 | 13.43 % |
| 5 | Revvity Inc | 1,234 | 5.2% |
| 6 | 10x Genomics Inc | 1,234 | 5.2% |
| 7 | Avantor Inc | 1,234 | 5.2% |
| 8 | Bio rad Laboratories Inc | 1,234 | 5.2% |
| 9 | Bruker Corporation | 1,234 | 5.2% |
| 10 | Alamar Biosciences Inc | 1,234 | 5.2% |
| 15 | Prenetics Global Limited | 257 | 0.11 % |
Market cap and industry share for the rest of Prenetics Global Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-01.
Prenetics Global Limited's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 10 | Alamar Biosciences Inc | 1,965 | - |
| 11 | Cytek Biosciences Inc | 757 | 71.55 % |
| 12 | Pacific Biosciences Of California Inc | 746 | 87.49 % |
| 13 | Eyepoint Inc | 296 | -75.71 % |
| 14 | Standard Biotools Inc | 1,234 | 12.3% |
| 15 | Prenetics Global Limited | 257 | 71.95 % |
| 16 | Nautilus Biotechnology Inc | 1,234 | 12.3% |
| 17 | Quanterix Corporation | 1,234 | 12.3% |
| 18 | Seer Inc | 1,234 | 12.3% |
| 19 | Kewaunee Scientific Corporation | 1,234 | 12.3% |
| 20 | Rapid Micro Biosystems Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Prenetics Global Limited's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-01. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Prenetics Global Limited's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Laboratory Analytical Instruments industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (45 companies). See the full Laboratory Analytical Instruments industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 53.15 % | 40.40 % (avg) | +12.7 pp |
| Operating Margin | -48.46 % | industry median | -31.5 pp |
| EBITDA Margin | -35.37 % | -18.55 % (avg) | -16.8 pp |
| Capital Intensity (Capex / Revenue) | 0.23 % | 3.93 % (avg) | -3.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Prenetics Global Limited's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 65.17 % | 39.82 % | 201.94 % |
| Operating Margin | - | - | -48.46 % |
| Return on Invested Capital | -11.19 % | -12.52 % | -11.70 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Prenetics Global Limited's Strategic Group Map
Every company in Prenetics Global Limited's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Prenetics Global Limited is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Prenetics Global Limited's BCG Growth-Share Matrix
Relative market share (vs Prenetics Global Limited's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Prenetics Global Limited falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 4.6% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Prenetics Global Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,464 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.23 % vs industry average 3.93 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Prenetics Global Limited's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Prenetics Global Limited's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Prenetics Global Limited's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Prenetics Global Limited falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Prenetics Global Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 31.5 points below the industry median.
- Return on equity 34.2 points below the industry aggregate.
- Low relative market share vs the industry leader (0.01x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Prenetics Global Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Prenetics Global Limited | 1.12 | 2.97 | 0.00 |
| Natera Inc | - | 3.14 | 0.05 |
| Illumina Inc | - | 1.74 | 0.75 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Revvity Inc | 0.74 | 1.74 | 0.45 |
| Caredx Inc | 1.68 | 3.47 | - |
Sign in to see all peers for Prenetics Global Limited.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Prenetics Global Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Prenetics Global Limited | Q4 2025 | +201.9 % | - |
| Natera Inc | Q2 2026 | +37.7 % | - |
| Illumina Inc | Q2 2026 | +9.4 % | -11.9 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Revvity Inc | Q2 2026 | +1.3 % | -3.9 % |
| Caredx Inc | Q2 2026 | +52.2 % | - |
| PEERS TOTAL | +16.4 % | - |
Sign in to see all peers for Prenetics Global Limited.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Prenetics Global Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Prenetics Global Limited | Q4 2025 | +186.4 % | -79.3 % |
| Natera Inc | Q2 2026 | -99.3 % | +144.9 % |
| Illumina Inc | Q2 2026 | +6.9 % | +33.3 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Revvity Inc | Q2 2026 | -4.5 % | -41.3 % |
| Caredx Inc | Q2 2026 | - | - |
Sign in to see all peers for Prenetics Global Limited.
Prenetics Global Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Prenetics Global Limited | - | - | - |
| Natera Inc | - | - | - |
| Illumina Inc | 12.68% | 19.61% | 31.08% |
| Guardant Health Inc | - | - | - |
| Revvity Inc | 1.97% | 2.18% | 3.27% |
| Caredx Inc | 24.81% | 29.42% | 32.81% |
Sign in to see all peers for Prenetics Global Limited.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Prenetics Global Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Prenetics Global Limited | - | - |
| Natera Inc | - | 21.62 |
| Illumina Inc | 49.76 | 9.05 |
| Guardant Health Inc | - | 19.63 |
| Revvity Inc | 72.01 | 5.71 |
| Caredx Inc | 32.00 | 7.72 |
| PEERS AVERAGE | 2,638.07 | 10.92 |
Sign in to see all peers for Prenetics Global Limited.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.